Non‐xenogeneic expansion and definitive endoderm differentiation of human pluripotent stem cells in an automated bioreactor

Citations Over Time

Abstract

Scalable processes are requisite for the robust biomanufacturing of human pluripotent stem cell (hPSC)-derived therapeutics. Toward this end, we demonstrate the xeno-free expansion and directed differentiation of human embryonic and induced pluripotent stem cells to definitive endoderm (DE) in a controlled stirred suspension bioreactor (SSB). Based on previous work on converting hPSCs to insulin-producing progeny, differentiation of two hPSC lines was optimized in planar cultures yielding up to 87% FOXA2+ /SOX17+ cells. Next, hPSCs were propagated in an SSB with controlled pH and dissolved oxygen. Cultures displayed a 10- to 12-fold increase in cell number over 5-6 days with the maintenance of pluripotency (>85% OCT4+ ) and viability (>85%). For differentiation, SSB cultures yielded up to 89% FOXA2+ /SOX17+ cells or ~ 8 DE cells per seeded hPSC. Specification to DE cell fate was consistently more efficient in the bioreactor compared to planar cultures. Hence, a tunable strategy is established that is suitable for the xeno-free manufacturing of DE cells from different hPSC lines in scalable SSBs. This study advances bioprocess development for producing a wide gamut of human DE cell-derived therapeutics.

Related Papers

• → Transformation of biomanufacturing by single-use systems and technology(2018)24 cited
• → Developing a Continuous Bioprocessing Approach to Stromal Cell Manufacture(2017)15 cited
• → Bioprocess Intensification: Technologies and Goals(2021)5 cited
• → Advanced Bioprocess Development and Biomanufacturing Technologies and High Throughput Miniature Bioreactors(2016)